对阿尔茨海默病早期变化的加速细胞模型的开发
Huijing Xue1, Sylvester Gate2, Emma Gentry1
1Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD, 20742, USA.
Scientific reports
|October 26, 2023
概括
引入孕素加速了阿尔茨海默病 (AD) 的建模. 这种与过早衰老相关的蛋白质有助于创建快速显示AD标志的细胞模型,有助于药物发现.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默氏病 (AD) 的发病原因尚不清楚,目前的细胞模型缺乏衰老环境,延迟了表型观察.
- 层A对核层结构至关重要;突变导致哈森-吉尔福德进发症综合征 (HGPS),这是一个过早衰老的疾病.
- 拉敏A表达在AD大脑中增加,HGPS和AD之间的细胞表现型重叠.
研究的目的:
- 为了研究外源性孕激素表达对家族性阿尔茨海默病 (FAD) 神经前体细胞的影响.
- 为了确定progerin是否可以在体外加速AD细胞表型的发展.
- 评估progerin在制造药物查加速AD模型方面的潜力.
主要方法:
- 外源性孕在具有家族AD突变的神经前体细胞中得到表达.
- 细胞分化了三到四周.
- 分析了关键的AD表型,细胞死亡和细胞周期重新进入.
主要成果:
- 进激素表达在几周内加速了强大的AD表型的发展.
- 观察到的表型包括酸化的增加,粉样斑块的积累,以及改变的Aβ42 / Aβ40比率.
- 普罗格林显著增强了与AD相关的细胞死亡和细胞循环重新进入.
结论:
- 进激素表达可以显著加快AD细胞表现型的表现.
- 这种方法为开发阿尔茨海默病的加速体外模型提供了一种新的方法.
- 进激素诱导的细胞模型显示了有效的AD药物查和开发的前景.
更多相关视频
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.3K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
相关概念视频
01:26Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
01:22Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200